Chugai Pharmaceutical Co (MEX:4519N) Beta: 0.2043 (As of Jul. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:4519N Chugai Pharmaceutical Co Ltd MEX:4519N
97 GF Score
Price MXN825.61
GF Value MXN873.09
! 1 Warning Sign
View Full Analysis

What is Chugai Pharmaceutical Co Beta?

Chugai Pharmaceutical Co MEX:4519N 97 Beta is 0.2043 as of Jul. 21, 2026. GuruFocus rates MEX:4519N with a GF Score™ of 97/100 and a GF Value™ of MXN873.09. The stock has 1 warning sign investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-21), Chugai Pharmaceutical Co's Beta is 0.2043.


Chugai Pharmaceutical Co  (MEX:4519N) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Chugai Pharmaceutical Co Beta Related Terms


Chugai Pharmaceutical Co Beta Historical Data

* Premium members only.

The historical data trend for Chugai Pharmaceutical Co's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chugai Pharmaceutical Co Beta Chart

Chugai Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.16 0.32

Chugai Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.21 0.43 0.24 0.32 0.22

MEX:4519N vs LLY, JNJ, ABBV: Beta Comparison

For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chugai Pharmaceutical Co Beta vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's Beta distribution charts can be found below:

* The bar in red indicates where Chugai Pharmaceutical Co's Beta falls into.


MEX:4519N
97GF Score
Chugai Pharmaceutical Co Ltd MEX:4519N
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chugai Pharmaceutical Co Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.2043 mean?
Chugai Pharmaceutical Co (MEX:4519N) has a Beta of 0.2043 as of Jul. 21, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Chugai Pharmaceutical Co and its competitors.
Is Chugai Pharmaceutical Co's Beta too high?
Chugai Pharmaceutical Co's current Beta is 0.2043. Overall, Chugai Pharmaceutical Co has a GF Score™ of 97/100, reflecting its overall financial health beyond just this single metric.
How does Chugai Pharmaceutical Co's Beta compare to LLY and JNJ?
Chugai Pharmaceutical Co's Beta of 0.2043 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Drug Manufacturers company?
A good Beta depends on the Drug Manufacturers industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Chugai Pharmaceutical Co and its competitors. Chugai Pharmaceutical Co's current Beta is 0.2043. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chugai Pharmaceutical Co stock overvalued right now?
Chugai Pharmaceutical Co (MEX:4519N) has a current Beta of 0.2043. The stock's GF Value™ is MXN873.09, compared to a current price of MXN825.61 — trading 5.4% below its estimated fair value. The current Beta is 0.2043. Chugai Pharmaceutical Co's overall GF Score™ is 97/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Chugai Pharmaceutical Co (MEX:4519N), the current Beta is 0.2043 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chugai Pharmaceutical Co (MEX:4519N) Overvalued in 2026?

Based on GuruFocus' analysis, Chugai Pharmaceutical Co stock appears to be undervalued. The current stock price of MXN825.61 is trading 5.4% below its estimated GF Value™ of MXN873.09.

Key valuation signals for MEX:4519N:

  • Beta: 0.2043
  • GF Value™: MXN873.09 vs. price of MXN825.61 (5.4% below fair value)
  • GF Score™: 97/100 with 1 warning sign

No single metric tells the full story. See the MEX:4519N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Chugai Pharmaceutical Co Business Description

Address 2-1-1 Muromachi, Nihonbashi, 12th Floor, Nihonbashi Mitsui Tower, Chuo-ku, Tokyo, JPN, 103-8324
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra (hemophilia), Actemra (rheumatoid arthritis, covid), Foundayo (oral obesity pill), and Nemluvio (atopic dermatitis, prurigo nodularis).
97GF Score

Get the complete analysis for MEX:4519N

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN825.61
Price
MXN873.09
GF Value